Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223)

NCT00503529 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00503529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00503529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223)
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2007
Completion date
September 30, 2010
Enrollment
314 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

encephalitis, tick-borne